June 2018 – Oxford Vacmedix ROP technology presented at 2018 Myongji International Cancer Symposium View in PDF
Oxford Vacmedix UK Limited (OVM) has completed its Series A financing round of $12.5m (£9m). Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company focused on the development of cancer vaccines, has completed its Series A financing round of $12.5m (£9m) with a consortium of South Korean and Chinese investors, including Cancer ROP, a leading …
Biopharmadealmakers.nature.com | September 2017; Oxford Vacmedix Ltd.: harnessing the power of immunotherapy to treat and monitor cancer View in PDF
Lili Cai, Jianbo Zhang et al, Oncotarget August 24, 2017 View in PDF
Melief CJ, van der Burg SH. Nat Rev Cancer. 2008 May;8(5):351-60.
Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. J Clin Invest. 2015 Sep;125(9):3401-12. View in PDF
Zhang, H et al. The Journal of Biological Chemistry, VOL.284,NO.14,pp.9184–9191, April 3,2009 View in PDF